Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Gains from Sales and Divestitures (2022 - 2025)

Kiniksa Pharmaceuticals International (KNSA) has disclosed Gains from Sales and Divestitures for 4 consecutive years, with $698136.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Gains from Sales and Divestitures rose 15.63% year-over-year to $698136.0, compared with a TTM value of $698136.0 through Sep 2025, up 15.63%, and an annual FY2022 reading of $250805.0, changed N/A over the prior year.
  • Gains from Sales and Divestitures was $698136.0 for Q3 2025 at Kiniksa Pharmaceuticals International, up from $342204.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $698136.0 in Q3 2025 and bottomed at $54349.0 in Q1 2025.
  • Average Gains from Sales and Divestitures over 4 years is $285807.5, with a median of $250805.0 recorded in 2022.
  • The sharpest move saw Gains from Sales and Divestitures soared 103.31% in 2023, then crashed 52.54% in 2024.
  • Year by year, Gains from Sales and Divestitures stood at $250805.0 in 2022, then soared by 85.76% to $465891.0 in 2023, then grew by 29.59% to $603762.0 in 2024, then increased by 15.63% to $698136.0 in 2025.
  • Business Quant data shows Gains from Sales and Divestitures for KNSA at $698136.0 in Q3 2025, $342204.0 in Q2 2025, and $54349.0 in Q1 2025.